Venrock Healthcare Capital led a €308m Series C round in Tubulis.

Venrock Healthcare Capital, a venture capital firm, led a €308m Series C round in Tubulis, a developer of chemotherapeutic drugs, with participation from Wellington Management, Ascenta Capital, Nextech Invest, EQT Life Sciences, Frazier Life Sciences, Andera Partners, Deep Track Capital, Bayern Kapital, Fund+, High-Tech Gründerfonds (HTGF), OCCIDENT, and Seventure Partners. “This landmark financing round reflects the deep conviction these global healthcare investors have in Tubulis and the disruptive potential of our ADC platforms,” Dr. Dominik Schumacher, Tubulis CEO and Co-founder.